Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Taspoglutide

Stage Phase 3Stale

Sponsor Hoffmann-La Roche

Class GLP-1 RA

Mechanism GLP-1 receptor agonist

Sources

registry, as of 2016-07-28Stale

https://clinicaltrials.gov/study/NCT00823992

A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy. Overall status COMPLETED. Phases PHASE3. Lead sponsor Hoffmann-La Roche. Enrollment 305. Conditions Diabetes Mellitus Type 2. This 2 arm study will assess the efficacy, safety and tolerability of taspoglutide compared to placebo in obese patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy. Patients will be randomized to receive taspoglutide (10mg sc once weekly for

ClinicalTrials.gov NCT00823992 protocol and results modules

publication, as of 2022-02-08Stale

https://pubmed.ncbi.nlm.nih.gov/34260945/

Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes. The glucagon-like peptide-1 receptor (GLP-1R) regulates insulin secretion, carbohydrate metabolism, and appetite and is an important target for treatment of type 2 d

PMID 34260945

Studies

A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy

Registry NCT00823992

Phase Phase 3

Status Completed

Enrollment 305

placebo

Regimen once weekly

Weeks 4

Population Diabetes Mellitus Type 2

taspoglutide

Regimen once weekly

Weeks 4

Comparator placebo

Population Diabetes Mellitus Type 2